Leslie Storms, U.S. president of Ethicon, Martha Shadan, chairwoman of Brilliant Springs Therapeutics, and Kristine Ilaria, vice president of Corporate Development at Smith+Nephew, share lessons learned from their panel “Making Acquisition Strategy Succeed: Perspectives from Both Sides of The Deal.”
The dynamics of the joint reconstruction devices industry has strengthened with consistent technological improvements, including the adoption of 3-D printing.
The adoption of this manufacturing process in healthcare saw a tremendous uptick in 2020.
The deal will strengthen Stryker’s portfolio of smart technologies in its joint replacement business and provide products that help physicians make data-driven decisions.
Although the medtech industry is expected to enjoy steady growth, device companies are still challenged to attract the skilled labor that manufacturing requires.
The deal is expected to close in the second half of 2020, but one analyst expects the transaction will raise antitrust issues in the United States.
A U.S. launch of the product is expected in just a few weeks.
By simplifying labeling compliance, companies can focus on better serving current and new markets.
Developing medical devices in general is costly, but there is funding available for companies that are willing to create products specifically for pediatrics.
Reparative medicine technology is an option to delay or avoid orthopedic surgery.